OUR DEVELOPMENT PIPELINE

In order to optimize the success of its Research and Development projects, Servier has decided to focus its efforts in four therapeutic areas with considerable needs—oncology, immuno-inflammation, neuroscience and cardiometabolism.

ONCOLOGY

CARDIOMETABOLISM

NEUROSCIENCE

IMMUNO-INFLAMMATION

UPDATE APRIL 2022

ONCOLOGY

Solid tumors

COMPOUND / MOA

PROJECT

THERAPEUTIC AREA

TERRITORY

PHASE

PARTNER

FTD/TPI combo bevacizumab

S95005

Solid tumors (new indication)

Worldwide ex-US/CAN, MEX & Asia

PCD

1

2

3

FTD/TPI combo futuximab / modotuximab

S95026

Solid tumors (new indication)

Worldwide ex-US/CAN, MEX & Asia

PCD

1

2

3

Vorasidenib

S95032

Low grade Glioma with IDH 1/2 mutation

Worldwide

PCD

1

2

3

Anti-MET

S95027

Non small Cell Lung Cancer

Worldwide

PCD

1

2

3

Vorasidenib combo

S95032

Enhancing Grade 2-3 glioma with IDH1/2 mutation

Worldwide

PCD

1/2

3

Ivosidenib combo

S95031

Solid tumors (new indication)

Worldwide

PCD

1/2

3

Anti-TIM3, anti-PD1, combo irinotecan

S95018

2nd line Biliary Tract Cancer and Esophageal squamous cell carcinoma

Worldwide

PCD

1/2

3

Anti-CD73

S95024

Solid Tumors

Worldwide

PCD

1/2

3

Anti-PD-L1/4-1BB

S95012

Solid Tumors

Worldwide ex-US

PCD

1/2

3

NKG2A

S95029

Solid Tumors

Worldwide

PCD

1/2

3

MAT2A inhibitor (+/- taxane-based chemotherapy)

S95033

1st & 2nd line Metastatic Pancreatic Ductal Adenocarcinoma and Esophagal squamous cell carcinoma with MTAP-deletion

Worldwide

PCD

1/2

3

Anti-LAG3

S95017

Solid Tumors

Worldwide

PCD

1/2

3

MAT2A inhibitor

S95035

Solid Tumors

Worldwide

PCD

1

2

3

Hematological malignancies

COMPOUND / MOA

PROJECT

THERAPEUTIC AREA

TERRITORY

PHASE

PARTNER

Ivosidenib combo azacitidine

S95031

Hematological malignancies (new indication)

Worldwide

PCD

1

2

3

Licensed in China

Ivosidenib combo 7+3 (chemo)

S95031

Hematological malignancies (new indication)

Worldwide

PCD

1

2

3

Licensed in China

UCART 19

S68587/S95023

Hematological malignancies

Worldwide ex-US

PCD

1

2

3

Calaspargase pegol

S95015

Hematological malignancies (new indication)

Worldwide

PCD

1

2

3

Pegaspargase

S95014

Hematological malignancies (new indication)

Worldwide

PCD

1

2

3

Ivosidenib

S95031

Hematological malignancies (new indication)

Worldwide

PCD

1/2

3

Licensed in China

BCL-2 inhibitor

S65487

Acute Myeloid Leukemia

Worldwide ex-US/CAN, JAP, some EU countries

PCD

1/2

3

Mcl1 inhibitor

S64315

Hematological malignancies

Worldwide ex-US/CAN, JAP, some EU countries

PCD

1/2

3

Mcl1 inhibitor

S216096

Hematological malignancies

Worldwide ex-US/CAN, JAP, some EU countries

PCD

1

2

3

CARDIOMETABOLISM

Metabolism

NEUROSCIENCE

COMPOUND / MOA

PROJECT

THERAPEUTIC AREA

TERRITORY

PHASE

PARTNER

Agomelatine

S20098

Psychiatry (new indication)

Worldwide

PCD

1

2

3

LRRK2

S221237

Parkinson’s Disease

Worldwide

PCD

1

2

3

IMMUNO-INFLAMMATION

COMPOUND / MOA

PROJECT

THERAPEUTIC AREA

TERRITORY

PHASE

PARTNER

Anti-IL7R

S95011

Sjögren syndrome

Worldwide

PCD

1

2

3

Anti-IL7R

S95011

Ulcerative colitis

Worldwide

PCD

1

2

3